The Fate of Beta-Cells in Type 2 Diabetes and the Possible Role of Pharmacological Interventions

Abstract

This article gives an overview of two recent trials investigat- ing rosiglitazone, a thiazolidinedione, in its potential to pre- vent type 2 diabetes (T2D) and in its effectiveness in mono- therapy. Thiazolidinediones are among the most important developments of recent years for combating T2D and there- fore worth to revisit. The possible influence of thiazolidines in improving beta-cell function is discussed as well as the potential effects on insulin resistance and obesity. Novel, incretin-based therapies (GLP-1 analogues and DPP-4 in- hibitors) and their effects on beta-cell function and beta-cell mass are also summarized and critically evaluated.